RPG Life Sciences Share Price
2679.90+27.50 (+1.04%)
+13.11% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 8% |
| - | - | - | -37% |
| 20% | 34% | 31% | 12% |
| 27% | 27% | 27% | 20% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
RPGLIFE
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,907.1 | ₹456833 Cr | 37.77 | 12.07 | 62.82 | ₹11479 Cr |
| 9,184 | ₹245426 Cr | 83.91 | 34.04 | 128.41 | ₹2568 Cr |
| 4,905 | ₹187320 Cr | 85.89 | 16.72 | 97.06 | ₹2163 Cr |
| 1,134 | ₹113217 Cr | 25.09 | 9.42 | 62.53 | ₹5040 Cr |
| 1,385.8 | ₹112212 Cr | 33.29 | 9.77 | 57.87 | ₹3879 Cr |
| 1,857.4 | ₹101155 Cr | 92.52 | 6.8 | 29.25 | ₹889 Cr |
| 2,124.9 | ₹97626 Cr | 17.66 | 30.95 | 154.36 | ₹5333 Cr |
| 2,356.5 | ₹96859 Cr | 47.42 | 13.75 | 71.08 | ₹1913 Cr |
| 1,163.3 | ₹96406 Cr | 29.92 | 5.32 | 63.99 | ₹4196 Cr |
| 1,645 | ₹93614 Cr | 25.22 | 17.95 | 96.84 | ₹3505 Cr |
| 2,679.9 | ₹4401 Cr | 38.21 | 18.6 | 82.62 | ₹115 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|
| ₹196 Cr | ₹177 Cr | ₹180 Cr | ₹169 Cr | ₹143 Cr | ₹173 Cr |
| ₹5 Cr | ₹12 Cr | ₹3 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr |
| ₹200 Cr | ₹189 Cr | ₹183 Cr | ₹174 Cr | ₹148 Cr | ₹176 Cr |
| ₹158 Cr | ₹150 Cr | ₹146 Cr | ₹139 Cr | ₹123 Cr | ₹129 Cr |
| ₹48 Cr | ₹45 Cr | ₹43 Cr | ₹41 Cr | ₹31 Cr | ₹52 Cr |
| ₹63 L | ₹39 L | ₹25 L | ₹13 L | ₹18 L | ₹12 L |
| ₹41 Cr | ₹40 Cr | ₹29 Cr | ₹35 Cr | ₹135 Cr | ₹47 Cr |
| ₹31 Cr | ₹30 Cr | ₹22 Cr | ₹26 Cr | ₹117 Cr | ₹35 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 |
|---|---|
| — | — |
| ₹13 Cr | ₹13 Cr |
| ₹592 Cr | ₹517 Cr |
| ₹592 Cr | ₹517 Cr |
| ₹605 Cr | ₹531 Cr |
| ₹13 Cr | ₹0 |
| ₹3 Cr | -₹1 Cr |
| ₹3 Cr | ₹3 Cr |
| ₹7 Cr | ₹5 Cr |
| ₹27 Cr | ₹6 Cr |
| — | — |
| ₹97 Cr | ₹79 Cr |
| ₹33 Cr | ₹24 Cr |
| ₹30 Cr | ₹16 Cr |
| ₹161 Cr | ₹120 Cr |
| ₹793 Cr | ₹657 Cr |
| ₹18 Cr | ₹14 Cr |
| ₹20 Cr | ₹0 |
| — | — |
| ₹321 Cr | ₹276 Cr |
| ₹125 Cr | ₹104 Cr |
| ₹197 Cr | ₹172 Cr |
| ₹20 Cr | ₹4 Cr |
| ₹1 Cr | ₹1 Cr |
| ₹1 Cr | ₹1 Cr |
| ₹13 Cr | ₹3 Cr |
| ₹234 Cr | ₹192 Cr |
| — | — |
| ₹84 Cr | ₹126 Cr |
| ₹124 Cr | ₹93 Cr |
| ₹117 Cr | ₹87 Cr |
| ₹192 Cr | ₹140 Cr |
| ₹16 Cr | ₹10 Cr |
| ₹28 Cr | ₹10 Cr |
| ₹559 Cr | ₹465 Cr |
| ₹399 Cr | ₹345 Cr |
| ₹793 Cr | ₹657 Cr |
| ₹366 | ₹321 |
| ₹366 | ₹321 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 |
|---|---|
| ₹154 Cr | ₹233 Cr |
| -₹17 Cr | -₹76 Cr |
| -₹43 Cr | -₹26 Cr |
| ₹94 Cr | ₹131 Cr |
| ₹57 Cr | ₹78 Cr |
| ₹86 Cr | -₹42 Cr |
| -₹21 Cr | -₹27 Cr |
| ₹122 Cr | ₹9 Cr |
| ₹29 Cr | ₹20 Cr |
| ₹150 Cr | ₹29 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found